Home
About
FAQ
History (5)
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Dopamine
Frullania
Motor Activity
Retinal Vein Occlusion
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Results (10)
More Search Options
Sort
Query Relevance
Name (A-Z)
Name (Z-A)
Institution (A-Z)
Institution (Z-A)
Show
(choose columns)
Faculty Rank
Name
Institution
Why
Laura A. Cox PhD
Wake Forest School of Medicine
Why?
Wendy C. Moore MD
Wake Forest School of Medicine
Why?
Stephen Peters MD, PhD
Wake Forest School of Medicine
Why?
Eric C. Donny PhD
Wake Forest School of Medicine
Why?
James C. Eisenach MD
Wake Forest School of Medicine
Why?
Clark W. Pinyan MD, MPH
Wake Forest School of Medicine
Why?
Annette T. Hastie PhD
Wake Forest School of Medicine
Why?
Gregory A. Hawkins PhD
Wake Forest School of Medicine
Why?
Roger M. Vilardaga Viera
Why?
Rodolfo M. Pascual MD
Wake Forest School of Medicine
Why?
Per Page
15
25
50
100
Page
of 1
Next
Prev
Search Criteria
Breath Tests
Click "Why?" to see why a person matched the search.
Search Options
Modify Search
Search Other Institutions